Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial

Ashish Bavdekar, Jitendra Oswal, Padmasani Venkat Ramanan, Chandrashekhar Aundhkar, P Venugopal, Dhananjay Kapse, Tara Miller, Sarah McGray, Darin Zehrung, Prasad S Kulkarni, SII MMR author group, D Ramaganeshan, Amita Sapru, Anand Pandit, Anand Kawade, Sanjay Lalwani, Sonali Palkar, Nita Hanumante, Nandini Malshe, Vidya Krishna, S Y Ingale, Bhagwat Gunale, Amol Chaudhari, Laura Saganic, Courtney Jarrahian, Ashish Bavdekar, Jitendra Oswal, Padmasani Venkat Ramanan, Chandrashekhar Aundhkar, P Venugopal, Dhananjay Kapse, Tara Miller, Sarah McGray, Darin Zehrung, Prasad S Kulkarni, SII MMR author group, D Ramaganeshan, Amita Sapru, Anand Pandit, Anand Kawade, Sanjay Lalwani, Sonali Palkar, Nita Hanumante, Nandini Malshe, Vidya Krishna, S Y Ingale, Bhagwat Gunale, Amol Chaudhari, Laura Saganic, Courtney Jarrahian

Abstract

Background: We conducted a randomized, non-inferiority, clinical study of MMR vaccine by a disposable-syringe jet injector (DSJI) in toddlers in India in comparison with the conventional administration.

Methods: MMR vaccine was administered subcutaneously by DSJI or needle-syringe (N-S) to toddlers (15-18 months) who had received a measles vaccine at 9 months. Seropositivity to measles, mumps, and rubella serum IgG antibodies was assessed 35 days after vaccination. Non-inferiority was concluded if the upper limit of the 95% CI for the difference in the percent of seropositive between groups was less than 10%. Solicited reactions were collected for 14 days after vaccination by using structured diaries.

Results: In each study group, 170 subjects received MMR vaccine. On day 35, seropositivity for measles was 97.5% [95% CI (93.8%, 99.3%)] in the DSJI group and 98.7% [95% CI (95.5%, 99.8%)] in the N-S group; for mumps, 98.8% [95% CI (95.6%, 99.8%)] and 98.7% [95% CI (95.5%, 99.8%)]; and for rubella, 98.8% [95% CI (95.6%, 99.8%)] and 100% [95% CI (97.7%, 100.0%)]; none of the differences were significant. The day 35 post-vaccination GMTs in DSJI and N-S groups were measles: 5.48 IU/ml [95% CI (3.71, 8.11)] and 5.94 IU/ml [95% CI (3.92, 9.01)], mumps: 3.83 ISR [95% CI (3.53, 4.14)] and 3.66 ISR [95% CI (3.39, 3.95)] and rubella: 95.27 IU/ml [95% CI (70.39, 128.95)] and 107.06 IU/ml [95% CI (79.02, 145.06)]; none of the differences were significant. The DSJI group reported 173 solicited local reactions and the N-S group reported 112; most were mild grade. Of the total of 156 solicited systemic adverse events, most were mild, and incidence between the two groups was similar.

Conclusions: MMR vaccination via DSJI is as immunogenic as vaccination by N-S. Safety profile of DSJI method is similar to N-S except for injection site reactions which are more with DSJI and are well-tolerated. Registration US National Institutes of Health clinical trials identifier - NCT02253407. Clinical trial registry of India identifier - CTRI/2013/05/003702.

Keywords: Disposable-syringe jet injector (DSJI); Immunogenicity; Measles-mumps-rubella (MMR) vaccine; Needle-free; Safety; Vaccination.

Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Stratis SC/IM (0.5 ml fixed dose).
Fig. 2
Fig. 2
Study flowchart.

References

    1. World Health Organization. Measles fact sheet; 2017. [accessed 7.12.17].
    1. World Health Organization. Rubella fact sheet; 2017. [accessed 7.12.17].
    1. World Health Organization. Recommended routine immunizations for children; 2017. [accessed 7.12.17].
    1. World Health Organization (WHO). Global measles and rubella strategic plan 2012–2020. Geneva (Switzerland): WHO; 2012. [accessed 20.10.16].
    1. World Health Organization (WHO). Global vaccine action plan. Monitoring, evaluation & accountability. Secretariat annual report. Geneva (Switzerland): WHO; 2015. [accessed 20.10.16].
    1. Zehrung D, Jarrahian C. Technologies to improve immunization. In: Bloom B, Lambert P-H, editors. The vaccine book, second ed. Cambridge (MA): Academic Press; 2016.
    1. John Clements C., Larsen Gordon, Jodar Luis. Technologies that make administration of vaccines safer. Vaccine. 2004;22:2054–2058.
    1. de Menezes Martins R, Curran B., Maia Mde L., Ribeiro Md., Camacho L.A., da Silva Freire M. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study. Contemp Clin Trials. 2015;41:1–8.
    1. Special 510(k) Premarket Notification, PharmaJet®, Inc., PharmaJet® stratis needle-free injection system; July 27, 2011, [accessed 20.10.16].
    1. PharmaJet. Stratis IM/SC; 2016. [accessed 20.10.16].
    1. PharmaJet. PharmaJet’s Stratis® needle-free injector receives WHO PQS certification as a pre-qualified delivery device for vaccine administration [blog post]; February 20, 2013. [accessed 20.10.16].
    1. International Committee on Harmonization. Medical dictionary for regulatory activities (MedDRA); 2016. , [accessed 20.10.16].
    1. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447–1454.
    1. McAllister Linda, Anderson Jonathan, Werth Kristen, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial; 2014 [published online May 30, 2014], 10.1016/S0140-6736(14)60524-9.
    1. Coughlin M.M., Collins M., Saxon G., Jarrahian C., Zehrung D., Cappello C. Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model. Vaccine. 2015;33(36):4540–4547.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다